Correlation between IKBKE and Aurora A expression and clinicopathological features in human gliomas

doi:10.3877/cma.j.issn.1674-0785.2025.04.004

Abstract

Abstract:

Objective

To detect the expression of IKBKE and Aurora A in normal brain tissues and glioma tissues and analyze their correlation with clinicopathological features.

Methods

Seventy-four cases of glioma tissues and 12 cases of normal brain tissues were collected at Henan Provincial People's Hospital from November 2020 to May 2022. Immunohistochemical method was used to detect the expression of IKBKE and Aurora A in these tissues, and their relationship with pathological grade, gender, tumor size, and other clinical parameters was analyzed.

Results

The expression of IKBKE and Aurora A was significantly different between normal brain tissues and glioma tissues of different pathological grades (P<0.001), and were significantly correlated with the pathological grades of glioma tissues (P<0.001). However, they exhibited no significant correlation with gender, number of invaded lobes, or tumor size (P>0.05). Spearman correlation analysis showed that there was a highly positive correlation between IKBKE and Aurora A expression (r=-0.9187, P<0.001).

Conclusion

The high expression of IKBKE and Aurora A is closely related to the malignant degree of glioma, and they may promote the progression of glioma through synergistic action, suggesting their value as potential therapeutic targets.

Key words: Brain glioma, IKBKE, Aurora A, Immunohistochemistry

Yang Liu, Hao Liang, Jie Gao, Lin Zhu, Yangguang Cui, Gaochao Guo, Tao Gao, Yuxue Sun, Ziqiang Liu, Chaoyue Li, Liming Zhao. Correlation between IKBKE and Aurora A expression and clinicopathological features in human gliomas[J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(04): 263-268.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2025.04.004

https://zhlcyszz.cma-cmc.com.cn/EN/Y2025/V19/I04/263

Figures/Tables 6

References 22

1	Wu A, Lim M. The challenges and future of immunotherapy for gliomas [J]. Cancer J, 2021, 27(5): 371-378.
2	Cai J, Hu Y, Ye Z, et al. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma [J]. Front Immunol, 2022, 13: 1011757.
3	Ali A, Stukenberg PT. Aurora kinases: generators of spatial control during mitosis [J]. Front Cell Dev Biol, 2023, 11: 1139367.
4	D’Assoro AB, Haddad T, Galanis E. Aurora-A kinase as a promising therapeutic target in cancer [J]. Front Oncol, 2016, 5: 295.
5	张懿炜, 胡亚欣, 出良钊, 等. CREB3通过下调FAK磷酸化水平抑制胶质瘤细胞增殖及侵袭转移的体外实验研究 [J/OL]. 中华临床医师杂志(电子版), 2023, 17(2): 202-209.
6	Shen L, Zhang Z, Wu P, et al. Mechanistic insight into glioma through spatially multidimensional proteomics [J]. Sci Adv, 2024, 10(7): eadk1721.
7	Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene [J]. Cell, 2007, 129(6): 1065-1079.
8	Guo JP, Shu SK, He L, et al. Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer [J]. Am J Pathol, 2009, 175(1): 324-333.
9	Péant B, Diallo J, Dufour F, et al. Over‐expression of IκB‐kinase‐ε (IKKε/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines [J]. The Prostate, 2009, 69(7): 706-718.
10	Kang MR, Kim MS, Kim SS, et al. NF-κB signalling proteins p50/p105, p52/p100, RelA, and IKKε are over-expressed in oesophageal squamous cell carcinomas [J]. Pathology, 2009, 41(7): 622-625.
11	Challa S, Guo JP, Ding X, et al. IKBKE is a substrate of EGFR and a therapeutic target in non-small cell lung cancer with activating mutations of EGFR [J]. Cancer Res, 2016, 76(15): 4418-4429.
12	Li H, Chen L, Zhang A, et al. Silencing of IKKε using siRNA inhibits proliferation and invasion of glioma cells in vitro and in vivo [J]. Int J Oncol, 2012, 41(1): 169-178.
13	Liu Y, Guo G, Lu Y, et al. Silencing IKBKE inhibits the migration and invasion of glioblastoma by promoting Snail1 degradation [J]. Clin Transl Oncol, 2022, 24(5): 816-828.
14	Liu Y, Lu J, Zhang Z, et al. Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines [J]. Cell Death & Disease, 2017, 8(8): e3022.
15	Yin M, Wang X, Lu J. Advances in IKBKE as a potential target for cancer therapy [J]. Cancer Medicine, 2019, 9(1): 247-258.
16	Xie W, Jiang Q, Wu X, et al. IKBKE phosphorylates and stabilizes Snail to promote breast cancer invasion and metastasis [J]. Cell Death Differ, 2022, 29(8): 1528-1540.
17	Leonardi M, Perna E, Tronnolone S, et al. Activated kinase screening identifies the IKBKE oncogene as a positive regulator of autophagy [J]. Autophagy, 2018, 15(2): 312-326.
18	Sankar S, Chan H, Romanow WJ, et al. IKK-i signals through IRF3 and NFkappaB to mediate the production of inflammatory cytokines [J]. Cell Signal, 2006, 18(7): 982-993.
19	Guan H, Zhang H, Cai J, et al. IKBKE is over-expressed in glioma and contributes to resistance of glioma cells to apoptosis via activating NF-κB [J]. J Pathol, 2011, 223(3): 436-445.
20	Tran TT, Vu LB, Nguyen HQ, et al. Dual roles of oxostephanine as an Aurora kinase inhibitor and angiogenesis suppressor [J]. Int J Mol Med, 2022 Nov;50(5):133.
21	李苗, 任正刚. Aurora A的功能及其在肝癌发生和发展中的作用 [J]. 中华肝脏病杂志, 2017, 25(6): 477-480.
22	Zheng D, Li J, Yan H, et al. Emerging roles of Aurora-A kinase in cancer therapy resistance [J]. Acta Pharm Sin B, 2023, 13(7): 2826-2843.

类别	例数	阴性（-）	弱阳性（+）	中度阳性（++）	强阳性（+++）	H值	P值
低级别胶质瘤	27	18（66.67）	7（25.92）	2（7.41）	0（0）	60.993	<0.001
高级别胶质瘤	47	0（0）	7（14.90）	11（23.40）	29（61.70）
正常脑组织	12	10（83.33）	2（16.67）	0（0）	0（0）

类别	例数	阴性（-）	弱阳性（+）	中度阳性（++）	强阳性（+++）	H值	P值
低级别胶质瘤	27	18（66.67）	7（25.92）	2（7.41）	0（0）	60.993	<0.001
高级别胶质瘤	47	0（0）	7（14.90）	11（23.40）	29（61.70）
正常脑组织	12	10（83.33）	2（16.67）	0（0）	0（0）

类别	例数	阴性（-）	弱阳性（+）	中度阳性（++）	强阳性（+++）	H值	P值
低级别胶质瘤	27	18（66.67）	7（25.92）	2（7.41）	0（0）	57.804	<0.001
高级别胶质瘤	47	2（4.26）	2（4.26）	21（44.68）	22（46.80）
正常脑组织	12	11（91.67）	1（8.33）	0（0）	0（0）

类别	例数	阴性（-）	弱阳性（+）	中度阳性（++）	强阳性（+++）	H值	P值
低级别胶质瘤	27	18（66.67）	7（25.92）	2（7.41）	0（0）	57.804	<0.001
高级别胶质瘤	47	2（4.26）	2（4.26）	21（44.68）	22（46.80）
正常脑组织	12	11（91.67）	1（8.33）	0（0）	0（0）

变量	例数	IKBKE表达				Aurora A表达
变量	例数	++/+++	-/+	χ²值	P值	++/+++	-/+	χ²值	P值
性别				2.093	0.148			0.364	0.547
男性	44	28/44（63.64）	16/44（36.36）			28/44（63.64）	16/44（36.36）
女性	30	14/30（46.67）	16/30（53.33）			17/30（56.67）	13/30（43.33）
年龄（岁）				8.314	0.004			6.336	0.012
<50	39	16/39（41.03）	23/39（58.97）			19/39（48.72）	20/39（51.28）
≥50	35	26/35（74.29）	9/35（25.71）			27/35（77.14）	8/35（22.86）
侵犯脑叶数（个）				0.184	0.668			1.300	0.254
<2	56	31/56（55.36）	25/56（44.64）			32/56（57.14）	24/56（42.86）
≥2	18	11/18（61.11）	7/18（38.89）			13/18（72.22）	5/18（27.78）
肿瘤大小				0.108	0.742			0.612	0.434
<5 cm	47	26/47（55.32）	21/47（44.68）			27/47（57.45）	20/47（42.55）
≥5 cm	27	16/27（59.26）	11/27（40.74）			18/27（66.67）	9/27（33.33）
病理分级（WHO）				42.182	0			50.873	<0.001
1~2级	27	2/27（7.41）	25/27（92.59）			2/27（7.41）	25/27（92.59）
3~4级	47	40/47（85.11）	7/47（14.89）			43/47（91.49）	4/47（8.51）

Please choose a citation manager

Content to export